CTMX

MKT CAP:$752M

CytomX Therapeutics, Inc.

Market Cap

$752M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$4.45+$0.20 (+4.71%)

Apr 23, 2026

Company Details

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product...

CEO

Sean A. McCarthy

IPO Date

Oct 8, 2015

Website

www.cytomx.com

Key Metrics TTM

Revenue

$76M

-44.8% YoY

Net Income

-$17M

EPS (Diluted)

$0.01

Free Cash Flow

-$76M

Revenue / Share

$0.45

Gross Margin

99.3%

Operating Margin

-29.4%

Net Margin

-22.8%

FCF Margin

-99.5%

P/S

9.9x

P/E

—

Earnings Reports

Q1 2026

May 11, 2026

PENDING

Q4 2025

Mar 16, 2026

$663.0K-98.3%EPS -$0.17

Q3 2025

Nov 6, 2025

$6M-82.2%EPS -$0.09

Q2 2025

Aug 7, 2025

$19M-25.7%EPS -$0.00

Q1 2025

May 12, 2025

$51M+22.8%EPS $0.27

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 21	$18M	$18M	-$23M
Q4 21	$20M	$18M	-$26M
Q1 22	$9M	$9M	-$32M
Q4 22	$20M	$20M	-$10M
Q1 23	$23M	$22M	-$6M
Q2 23	$25M	$23M	-$3M
Q3 23	$26M	$25M	$11M
Q4 23	$27M	$27M	-$606.0K
Q1 24	$41M	$41M	$12M
Q2 24	$25M	$25M	-$8M
Q3 24	$33M	$33M	$4M
Q4 24	$38M	$38M	$18M
Q1 25	$51M	$51M	$23M
Q2 25	$19M	$19M	-$1M
Q3 25	$6M	$6M	-$16M
Q4 25	$663.0K	$153.0K	-$28M

Valuation

Quarter	P/S	P/E
Q3 21	5.3x	—
Q4 21	4.2x	—
Q1 22	2.8x	—
Q4 22	2.9x	—
Q1 23	1.4x	—
Q2 23	1.9x	—
Q3 23	0.9x	—
Q4 23	1.1x	—
Q1 24	1.2x	8.8x
Q2 24	0.9x	9.8x
Q3 24	0.8x	7.2x
Q4 24	0.6x	2.7x
Q1 25	0.4x	1.3x
Q2 25	1.4x	4.1x
Q3 25	3.7x	14.9x
Q4 25	9.1x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 21	-$30M	-$30M
Q4 21	-$31M	-$31M
Q1 22	-$41M	-$42M
Q4 22	-$1M	-$2M
Q1 23	$9M	$9M
Q2 23	-$25M	-$26M
Q3 23	-$18M	-$18M
Q4 23	-$22M	-$22M
Q1 24	-$26M	-$26M
Q2 24	-$20M	-$20M
Q3 24	-$21M	-$21M
Q4 24	-$20M	-$20M
Q1 25	-$21M	-$21M
Q2 25	-$16M	-$16M
Q3 25	-$16M	-$15M
Q4 25	-$23M	-$23M

Capital Expenditures

Quarter	CapEx
Q3 21	$268.0K
Q4 21	$245.0K
Q1 22	$736.0K
Q4 22	$182.0K
Q1 23	$48.0K
Q2 23	$517.0K
Q3 23	$9.0K
Q4 23	$266.0K
Q1 24	$115.0K
Q2 24	$96.0K
Q3 24	$19.0K
Q4 24	$80.0K
Q1 25	$119.0K
Q2 25	$27.0K
Q3 25	$127.0K
Q4 25	$201.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 21	-1.1%	+23.1%
Q4 21	+20.5%	+47.8%
Q1 22	-43.4%	+30.1%
Q4 22	+23.5%	-16.5%
Q1 23	+33.6%	-27.5%
Q2 23	+25.3%	-39.0%
Q3 23	+191.9%	-62.8%
Q4 23	+32.2%	-8.2%
Q1 24	+76.4%	+2.2%
Q2 24	+1.6%	+19.6%
Q3 24	+26.7%	+91.8%
Q4 24	+43.2%	-25.0%
Q1 25	+22.8%	-5.1%
Q2 25	-25.7%	-40.6%
Q3 25	-82.2%	-25.9%
Q4 25	-98.3%	+40.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 21	$0	0.0%
Q4 21	$0	0.0%
Q1 22	$3M	37.3%
Q4 22	$0	0.0%
Q1 23	$2M	10.3%
Q2 23	$0	0.0%
Q3 23	$0	0.0%
Q4 23	$3M	9.6%
Q1 24	$2M	4.6%
Q2 24	$2M	7.5%
Q3 24	$2M	6.0%
Q4 24	$2M	4.9%
Q1 25	$2M	3.9%
Q2 25	$1M	7.7%
Q3 25	$2M	25.2%
Q4 25	$1M	223.1%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q3 21	$29M	$11M	—
Q4 21	$36M	—	$9M
Q1 22	$31M	$11M	—
Q4 22	$20M	$8M	—
Q1 23	$21M	—	$7M
Q2 23	$20M	—	$6M
Q3 23	$10M	—	$3M
Q4 23	$19M	$8M	—
Q1 24	$22M	$8M	—
Q2 24	$25M	$8M	—
Q3 24	$21M	$8M	—
Q4 24	$15M	$6M	—
Q1 25	$19M	$9M	—
Q2 25	$13M	$7M	—
Q3 25	$15M	$6M	—
Q4 25	$21M	—	$7M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$163M	$99M	$263M
Q2 22	$129M	$99M	$228M
Q3 22	$95M	$99M	$194M
Q4 22	$194M	$0	$194M
Q1 23	$56M	$148M	$205M
Q2 23	$58M	$123M	$181M
Q3 23	$26M	$168M	$194M
Q4 23	$17M	$157M	$175M
Q1 24	$36M	$114M	$150M
Q2 24	$43M	$94M	$137M
Q3 24	$41M	$77M	$118M
Q4 24	$38M	$63M	$101M
Q1 25	$48M	$32M	$80M
Q2 25	$49M	$109M	$158M
Q3 25	$34M	$109M	$144M
Q4 25	$13M	$124M	$137M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 21	65M	+0.2%	+41.2%
Q4 21	65M	0.0%	+41.2%
Q1 22	65M	+0.3%	+7.3%
Q4 22	66M	+1.3%	+1.8%
Q1 23	66M	+0.0%	+1.6%
Q2 23	67M	+0.4%	+2.0%
Q3 23	81M	+21.7%	+23.9%
Q4 23	67M	-16.9%	+1.6%
Q1 24	83M	+22.8%	+24.7%
Q2 24	85M	+2.7%	+27.6%
Q3 24	85M	+0.4%	+5.2%
Q4 24	80M	-6.0%	+19.0%
Q1 25	87M	+8.8%	+5.5%
Q2 25	129M	+48.1%	+52.1%
Q3 25	165M	+27.8%	+93.7%
Q4 25	170M	+3.1%	+112.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 21	$122.1K	144
Q4 21	$113.4K	174
Q1 22	$52.0K	174
Q4 22	$173.5K	116
Q1 23	$202.6K	116
Q2 23	$213.1K	116
Q3 23	$227.4K	116
Q4 23	$221.7K	120
Q1 24	$345.5K	120
Q2 24	$209.3K	120
Q3 24	$278.6K	120
Q4 24	$320.1K	119
Q1 25	$427.9K	119
Q2 25	$156.8K	119
Q3 25	$50.1K	119
Q4 25	$3	200K

Revenue / Employee